Clinical trials: Respiratory Inflammation
Allergic Rhinitis
Effects of Multiple Nasal Exposures to House Dust Mite Allergen on Nasal and Body Inflammation and Airway Sensitivity
This study will evaluate whether multiple nasal antigen challenges with dust mite allergen produces increases in nasal symptoms and local allergic inflammatory cells in the nose and the blood.
- Trial name
- NCT00513487
- Testing
- Dust mite extract, Fluticasone, Methacholine
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Novartis
Asthma
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
Primary Objective: To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: To evaluate the effect of dupilumab at Week 24 on…
- Trial name
- VESTIGE (NCT04400318)
- Testing
- Dupilumab
- Where
- 65 sites in United States, Bulgaria and 11 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Asthma
Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma
The purpose of this study is to determine the effectiveness and safety of reslizumab in the treatment of subjects with poorly controlled asthma.
- Trial name
- NCT00587288
- Testing
- Reslizumab, Saline
- Where
- 30 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Ception Therapeutics
Covid19, Cytokine Release Syndrome
Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
The purpose of this study is to assess the safety and efficacy of orally administered NLRP3 inhibitor, dapansutrile, for the treatment of moderate COVID-19 symptoms and early cytokine release syndrome (CRS) in patients with…
- Trial name
- NCT04540120
- Testing
- dapansutrile capsules
- Where
- 10 sites in United States, Switzerland
- Volunteers
- 49 people
- Sponsor
- Olatec Therapeutics, Inc.
Sepsis, Acute Lung Injury
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
This is a prospective, randomized (1:1), double-blind, multi-center, Phase II clinical study to test the safety and efficacy of a recombinant chimeric anti-tissue factor antibody (ALT-836) versus placebo in patients with sepsis…
- Conditions
- Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Trial name
- NCT00879606
- Testing
- ALT-836
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- Altor BioScience
Cardiac Arrest, Renal Failure
The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III
To evaluate the effect of automated recording on frequency of recorded scores, number of automated notifications and serious events.
- Conditions
- Cardiac Arrest, Renal Failure, Respiration Failure, Myocardial Infarction
- Trial name
- NCT02973243
- Testing
- Automatic RR Measurement
- Where
- United Kingdom
- Volunteers
- 446 people
- Sponsor
- Philips Healthcare
Atopic Asthma
Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects
The purpose of the study is to determine whether senicapoc can decrease changes in FEV1 following allergen challenge in atopic allergic subjects.
- Trial name
- NCT00861211
- Testing
- senicapoc
- Where
- 2 sites in United Kingdom
- Volunteers
- 34 people
- Sponsor
- Icagen
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
COPD Acute Exacerbation
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
- Trial name
- NCT06940154
- Testing
- Rademikibart in prefilled syringe
- Where
- 52 sites in United States, Argentina and 4 more
- Volunteers
- 159 people
- Sponsor
- Connect Biopharm LLC
Covid-19
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
This clinical trial will explore the safety and potential efficacy of CLBS119 for the repair of COVID-19 induced pulmonary damage in adults.
- Trial name
- NCT04522817
- Testing
- CLBS119
- Where
- United States
- Sponsor
- Lisata Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease
Objective: To characterize FeNO levels that may be indicative of eosinophilic airway inflammation in patients with chronic obstructive airways disease Number of participants: Approximately 200 subjects will be enrolled Reference…
- Trial name
- NCT01634620
- Testing
- NIOX MINO® Instrument (09-1100)
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Aerocrine AB
Infection
Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution
This study is a post-marketing surveillance in Japan to investigate the safety especially focusing on injection site adverse events and efficacy in patients with Ciprofloxacin iv administration without dilution in the daily…
- Trial name
- NCT01690559
- Testing
- Cipro (Ciprofloxacin, BAYQ3939)
- Where
- Japan
- Volunteers
- 704 people
- Sponsor
- Bayer
Airway Inflammation, Asthma
An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients
This is a randomised, active-comparator, open-label, parallel-group, multicentre phase IV exploratory study to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using SABA…
- Trial name
- NCT03924635
- Testing
- SYMBICORT and salbutamol
- Where
- 6 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
SARS-CoV-2 Acute Respiratory Disease
Study of the Evolution of Olfactory Disorders in Patients With Persistent Loss of Smell Following COVID-19
The COVID-19 pandemic is a novel medical challenge, particularly because of the systemic nature of this disease. Indeed, COVID-19 affects several organs and systems at once.
- Trial name
- ETOC (NCT05133596)
- Testing
- Clinical examination, Blood collection, Olfactory evoked potentials
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Institut Pasteur
Asthma
Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma
The purpose of this study is to investigate the effect on airway inflammation and JAK1-associated signalling pathways of AZD4604 compared with placebo in participants with moderate-to-severe asthma.
- Trial name
- ARTEMISIA (NCT06435273)
- Testing
- AZD4604
- Where
- 18 sites in Canada, Denmark and 3 more
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by Annualized rate of acute moderate or severe COPD…
- Trial name
- NOTUS (NCT04456673)
- Testing
- Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist
- Where
- 334 sites in United States, Argentina and 27 more
- Volunteers
- 935 people
- Sponsor
- Sanofi
Covid19, Bacteremia
Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia
Phage Treatment in Covid-19 Patients with Bacterial Co-Infections
- Conditions
- Covid19, Bacteremia, Septicemia, Acinetobacter Baumannii Infection
- Trial name
- NCT04636554
- Testing
- Phage Therapy
- Sponsor
- Adaptive Phage Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD
The purpose of this study is to assess the tolerability and efficacy of inhaled theophylline (ADC4022) on markers of pulmonary inflammation (white blood cells) in induced sputum and in bronchial biopsy samples in subjects with…
- Trial name
- NCT00634413
- Testing
- Theophylline - ADC4022, Budesonide
- Where
- 8 sites in Poland, United Kingdom
- Volunteers
- 91 people
- Sponsor
- Pulmagen Therapeutics
Respiratory Failure, Respiratory Arrest
Postoperative Respiratory Abnormalities
The study aims to determine how historical cases of respiratory abnormalities are documented by clinicians in the electronic health records (EHR) of Memorial Hermann Healthcare System (MHHS) inpatient facilities.
- Conditions
- Respiratory Failure, Respiratory Arrest, Respiratory Distress Syndrome, Acute Respiratory Failure
- Trial name
- AI-ARF (NCT04079829)
- Testing
- Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data
- Where
- United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Efficacy Care R&D Ltd
Asthma
The Effect Of AVANDIA On The Late Asthmatic Response
This study is to investigate the effects of AVANDIA on the asthmatic response.
- Trial name
- NCT00318630
- Testing
- Rosiglitazone
- Where
- New Zealand
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline